CTXR Jul 2024 2.500 call
| Previous Close | 0.0300 |
| Open | 0.0300 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 2.50 |
| Expire Date | 2024-07-19 |
| Day's Range | 0.0300 - 0.0300 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 184 |
ACCESSWIRESidoti Events, LLC's Virtual June Small-Cap Conference
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day June Small-Cap Conference taking place Wednesday and Thursday, June 12-13, 2024. ...
PR NewswireCitius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution.
- PR Newswire
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced positive topline results of its pivotal Phase 3 clinical trial of Mino-Lok®, a novel antibiotic lock solution designed to salvage catheters in patients with central line-associated infections (CLABSI) or catheter-related bloodstream infections (CRBSI). The study met its primary
